trial

Pharmacologic Modulation of Hippocampal Activity in Psychosis

NCTId NCT04277936
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 1 (actual)
Sponsored by Vanderbilt University Medical Center
Primary completion 2020-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
1 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2020-05-11
Primary completion
2020-08-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Levetiracetam 500 mg

Sponsors

Vanderbilt University Medical CenterLead Sponsor

Sites

1 total
Nashville, United States

Linked catalysts

1
Pharmacologic Modulation of Hippocampal Activity in Psychosis — primary completion2020-08-31

Facts & assertions

4 sourced
Enrollment
1
Phase
PHASE2
Primary Completion Date
2020-08-31
Status
TERMINATED
relationships
The graph out of here
drug
Levetiracetam 500 mg
drug
lead_sponsor
Vanderbilt University Medical Center
company
indication
Schizophrenia; Psychosis
indication
Schizophrenia
indication
Psychotic Disorders
indication